Core Insights - BioTissue Holdings, Inc. has completed the sale of its non-ocular Surgical and Wound Care business to BioStem Technologies, Inc., allowing BioTissue to focus on ocular market leadership and innovation in eye care solutions [1][2][3] Company Overview - BioTissue specializes in utilizing human birth tissue for regenerative healing, particularly in treating acute and chronic ocular surface conditions [4] - The company has developed a portfolio of cryopreserved amniotic membrane products using proprietary CryoTek® technology, which preserves the tissue's structural and functional integrity [4] - BioTissue has conducted over 1 million human procedures with its products and has over 420 peer-reviewed publications supporting its technology [4] Strategic Focus - Following the divestiture, BioTissue will concentrate on advancing interventional therapies for ocular conditions, including products like Prokera, CAM360 AmnioGraft, and AmnioGuard [2][3] - The company aims to prioritize product innovation, professional education, and comprehensive customer support within the eye care market [2] Partnership with BioStem - BioStem Technologies will acquire exclusive rights to BioTissue's Neox and Clarix product lines, integrating BioTissue's surgical sales team into its commercial organization [2][3] - BioStem's CEO highlighted the complementary strengths of BioTissue's portfolio to their existing business, indicating a strong potential for growth and improved patient outcomes [3]

Accelerates expansion of BioStem’s commercial organization through integration of an experienced national sales force Expands access to major GPO networks, strengthening BioStem’s position across hospital settings Barry Hassett promoted to Chief Commercial Officer Conference call scheduled for tomorrow, January 22nd at 8am ET POMPANO BEACH, Fla., Jan. 21, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercializatio ...

Decision ensures continued patient access to VENDAJE® and VENDAJE AC® POMPANO BEACH, Fla., Jan. 07, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today commented on the withdrawal of all seven of the Centers for Medicare & Medicaid Services’ (“CMS”) Local Coverage Determinations (“LCD”) for skin substitute grafts/cellular and tissue-based produc ...

Status Quo designation preserves DFU/VLU reimbursement eligibility for 2026, ensuring continued patient access to BioStem technology Coverage for the majority of BioStem’s non-acute revenue, treatment for pressure ulcers, also remains unaffected by CMS LCD updates POMPANO BEACH, Fla., Dec. 18, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today ...

Florida Medicaid Adds BioStem’s VENDAJE® and VENDAJE AC® to Covered Skin Substitutes ListPOMPANO BEACH, Fla., Nov. 25, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company specializing in placental-derived biologics for advanced wound care, today announced expanded reimbursement with the inclusion of VENDAJE® and VENDAJE AC® in Florida Medicaid’s list of covered skin substitutes. This expansion marks a significant milestone in BioStem’s national reimbursement strategy, ...

Core Insights - BioStem Technologies, Inc. supports the CMS's final rule on the Physician Fee Schedule for 2026, which aims to create a more transparent and sustainable reimbursement system for skin substitutes [2][4] - The new reimbursement model is expected to restore market balance and reward clinical performance, aligning with BioStem's goals for its BioREtain-processed placental allografts [2][3] Company Positioning - BioStem's BioREtain manufacturing process offers lower cost of goods sold (COGS) and scalable production, which is expected to maintain robust product margins under the new reimbursement model [3] - The company is well-positioned to thrive in the evolving reimbursement environment due to its clinically validated products and efficient cost structure [4] Clinical Validation - BioStem's commitment to scientific validation is highlighted by a Level 1 randomized controlled trial demonstrating superior patient outcomes with its products compared to standard care [2] - The company collaborates with clinical partners and policymakers to ensure that the reimbursement framework supports innovation and optimal patient care [4]

Core Insights - BioStem Technologies, Inc. is expanding its operations by purchasing land for a new headquarters in the Research Park at Florida Atlantic University, which will create up to 100 new jobs over the next five years with the support of up to $300,000 in economic incentives from the city [1][2][3] Company Overview - BioStem Technologies specializes in the development, manufacturing, and commercialization of placental-derived products for advanced wound care, utilizing its proprietary BioRetain processing method to maintain growth factors and preserve tissue structure [5] - The company’s quality management system is accredited by the American Association of Tissue Banks and adheres to current Good Tissue Practices and Good Manufacturing Processes [5] Economic Impact - The new headquarters will centralize administrative offices, manufacturing, and distribution, enhancing operational efficiency and supporting the growing demand for advanced wound care products [2][3] - The Research Park serves as a hub for technology companies and research organizations, fostering collaboration and innovation in South Florida's life sciences sector [3][4] Strategic Location - The choice of the Research Park location is strategic, providing access to a talented workforce and proximity to a university with strong science and healthcare programs [3] - The Research Park has been established as a center for entrepreneurial ideas and technologies since 1985, promoting economic growth in the region [3][4]

Core Insights - BioStem Technologies, Inc. will release its third quarter 2025 financial results on November 13, 2025, and will host a conference call and webcast at 4:30 PM ET [1][2] Company Overview - BioStem Technologies is a MedTech company focused on developing, manufacturing, and commercializing placental-derived products for advanced wound care [1][3] - The company utilizes its proprietary BioREtain processing method, which is designed to maintain growth factors and preserve tissue structure [3] - BioStem's quality management system has been accredited by the American Association of Tissue Banks (AATB) and complies with current Good Tissue Practices (cGTP) and current Good Manufacturing Processes (cGMP) [3] Product Portfolio - The company's product brands include AmnioWrap2™, VENDAJE, VENDAJE AC, and VENDAJE OPTIC, all processed at its FDA registered and AATB accredited site in Pompano Beach, Florida [3]

Core Insights - BioStem Technologies, Inc. has appointed KPMG LLP as its new independent registered public accounting firm, replacing Marcum LLP, effective October 22, 2025 [1][2] - The transition to KPMG is part of the company's strategy to support long-term growth and its planned uplisting to the Nasdaq Capital Market [2][3][4] Company Strategy - The company aims to proceed with its uplisting to the Nasdaq following the completion of audits for the fiscal years 2024 and 2025 [3] - Uplisting is considered a key priority for the company, expected to enhance visibility, improve stock liquidity, provide accurate market valuation, and attract top talent [4] Company Overview - BioStem Technologies focuses on developing, manufacturing, and commercializing placental-derived products for advanced wound care, leveraging its proprietary BioREtain processing method [4] - The company’s quality management system is accredited by the American Association of Tissue Banks and complies with current Good Tissue Practices and Good Manufacturing Processes [4]

Core Points - BioStem Technologies, Inc. has partnered with the Florida Panthers to sponsor the "Heroes Among Us" program, which honors military veterans during NHL home games [1][2] - The program has recognized over 500 military members since its inception in 2013, including veterans from various wars [2] - BioStem is also continuing its support for the "Seats for Service" initiative, providing game-day experiences for veterans and their families [4] Company Overview - BioStem Technologies is a MedTech company focused on developing and commercializing placental-derived products for advanced wound care [1][8] - The company utilizes its proprietary BioREtain processing method to maintain growth factors and preserve tissue structure in its allografts [8] - BioStem's quality management systems are accredited by the American Association of Tissue Banks, adhering to current Good Tissue Practices and Good Manufacturing Processes [8] Community Engagement - The "Heroes Among Us" program features a military hero at each home game, with a national anthem dedication and a video highlighting their story [2][3] - The Florida Panthers Foundation emphasizes veterans' affairs as one of its core pillars, supporting organizations that provide resources to military members [5] - The community can nominate veterans for the "Heroes Among Us" program through the Florida Panthers' website [3]